Matt Dobson - VentriPoint Diagnostics Marketing Director
| VPT Stock | CAD 0.17 0.01 6.25% |
Director
Matt Dobson is Marketing Director of VentriPoint Diagnostics
| Address | 18 Hook Avenue, Toronto, ON, Canada, M6P 1T4 |
| Phone | 416 848 4156 |
| Web | https://ventripoint.com |
VentriPoint Diagnostics Management Efficiency
The company has return on total asset (ROA) of (1.7166) % which means that it has lost $1.7166 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (29.726) %, meaning that it generated substantial loss on money invested by shareholders. VentriPoint Diagnostics' management efficiency ratios could be used to measure how well VentriPoint Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.44 in 2025. Return On Capital Employed is likely to climb to -11.07 in 2025. At this time, VentriPoint Diagnostics' Total Current Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 297.8 K in 2025, whereas Intangible Assets are likely to drop slightly above 30 K in 2025.VentriPoint Diagnostics has accumulated 274.38 K in total debt. VentriPoint Diagnostics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist VentriPoint Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, VentriPoint Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like VentriPoint Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for VentriPoint to invest in growth at high rates of return. When we think about VentriPoint Diagnostics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | DIRECTOR Age | ||
| Chris MBA | Reliq Health Technologies | N/A | |
Management Performance
| Return On Equity | -29.73 | ||||
| Return On Asset | -1.72 |
VentriPoint Diagnostics Leadership Team
Elected by the shareholders, the VentriPoint Diagnostics' board of directors comprises two types of representatives: VentriPoint Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VentriPoint. The board's role is to monitor VentriPoint Diagnostics' management team and ensure that shareholders' interests are well served. VentriPoint Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VentriPoint Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BASc ICDD, Ex CEO | ||
| Jim Graba, Application Trainer | ||
| CPA CMA, Chief Officer | ||
| Hirotaka Katagiri, CTO Director | ||
| Jimmy Jeon, Chief Officer | ||
| Hugh MacNaught, President CEO | ||
| Matt Dobson, Marketing Director | ||
| Jessica Naman, Director Marketing | ||
| Alvira Macanovic, Vice President - Operations Development | ||
| Desmond Hirson, Consultant | ||
| Bart Hendriks, Strategic Executive |
VentriPoint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VentriPoint Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -29.73 | ||||
| Return On Asset | -1.72 | ||||
| Operating Margin | (18.51) % | ||||
| Current Valuation | 28.5 M | ||||
| Shares Outstanding | 159.82 M | ||||
| Shares Owned By Insiders | 2.08 % | ||||
| Number Of Shares Shorted | 18.04 K | ||||
| Price To Earning | 47.50 X | ||||
| Price To Book | 7.13 X | ||||
| Price To Sales | 198.94 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for VentriPoint Stock Analysis
When running VentriPoint Diagnostics' price analysis, check to measure VentriPoint Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VentriPoint Diagnostics is operating at the current time. Most of VentriPoint Diagnostics' value examination focuses on studying past and present price action to predict the probability of VentriPoint Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VentriPoint Diagnostics' price. Additionally, you may evaluate how the addition of VentriPoint Diagnostics to your portfolios can decrease your overall portfolio volatility.